Adding more to this thread. High molecular risk (HMR) are considered in the MIPSS70+ version 2 scoring system for myelofibrosis prognosis. HMR are ASXL1, EZH2, SRSF2, IDH1/2, and U2AF1.

One can get very different results using this scoring system versus the standard DIPSS-plus system. In my case, I am “low risk” under DIPSS-plus while “high risk” on MIPSS70+v2. The main difference is reflecting HMR. My doctor is not treating me any differently knowing this discrepancy in scores — currently “watch and wait” with regular bloodwork as I am mostly asymptomatic. I do worry about having a greater chance of faster progression or eventual transformation to leukemia given the HMR.

Some related links:
http://www.mipss70score.it/

https://ashpublications.org/blood/article/130/S...

In addition to JAK2, I have a few other mutations. I’m not familiar with FBXW7. Some mutations are associated with poorer prognosis. The link below discusses mutations.

https://ashpublications.org/bloodadvances/artic...

I just have JAK2.

Thank you so much🫶🏼

I only show JAK now. Thank God 🙏